Anti-Ras (mutated G12D) antibody (ab221163)
Key features and details
- Rabbit polyclonal to Ras (mutated G12D)
- Suitable for: WB, IHC-P
- Reacts with: Human
- Isotype: IgG
Overview
-
Product name
Anti-Ras (mutated G12D) antibody
See all Ras primary antibodies -
Description
Rabbit polyclonal to Ras (mutated G12D) -
Host species
Rabbit -
Specificity
G12D mutant specific. -
Tested applications
Suitable for: WB, IHC-Pmore details -
Species reactivity
Reacts with: Human
Predicted to work with: Mouse, Rat, Chicken, Guinea pig, Cow, Dog, Pig, Xenopus laevis, Zebrafish -
Immunogen
Synthetic peptide corresponding to Human Ras (N terminal) (mutated G12D). (Carrier-protein conjugated).
Database link: P01111 -
Positive control
- Human colon cancer tissue; AsPC-1 whole cell extract; Ras (mutant G12D) transfected 293T whole cell extracts.
-
General notes
The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C long term. Avoid freeze / thaw cycle. -
Storage buffer
pH: 7.00
Preservative: 0.025% Proclin 300
Constituents: 78% PBS, 1% BSA, 20% Glycerol (glycerin, glycerine) -
Concentration information loading...
-
Purity
Immunogen affinity purified -
Clonality
Polyclonal -
Isotype
IgG -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab221163 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
WB |
1/500 - 1/10000. Predicted molecular weight: 21 kDa.
|
|
IHC-P | (1) |
1/100 - 1/1000.
|
Notes |
---|
WB
1/500 - 1/10000. Predicted molecular weight: 21 kDa. |
IHC-P
1/100 - 1/1000. |
Target
-
Function
Ras proteins bind GDP/GTP and possess intrinsic GTPase activity. -
Involvement in disease
Defects in HRAS are the cause of faciocutaneoskeletal syndrome (FCSS) [MIM:218040]. A rare condition characterized by prenatally increased growth, postnatal growth deficiency, mental retardation, distinctive facial appearance, cardiovascular abnormalities (typically pulmonic stenosis, hypertrophic cardiomyopathy and/or atrial tachycardia), tumor predisposition, skin and musculoskeletal abnormalities.
Defects in HRAS are the cause of congenital myopathy with excess of muscle spindles (CMEMS) [MIM:218040]. CMEMS is a variant of Costello syndrome.
Defects in HRAS may be a cause of susceptibility to Hurthle cell thyroid carcinoma (HCTC) [MIM:607464]. Hurthle cell thyroid carcinoma accounts for approximately 3% of all thyroid cancers. Although they are classified as variants of follicular neoplasms, they are more often multifocal and somewhat more aggressive and are less likely to take up iodine than are other follicular neoplasms.
Note=Mutations which change positions 12, 13 or 61 activate the potential of HRAS to transform cultured cells and are implicated in a variety of human tumors.
Defects in HRAS are a cause of susceptibility to bladder cancer (BLC) [MIM:109800]. A malignancy originating in tissues of the urinary bladder. It often presents with multiple tumors appearing at different times and at different sites in the bladder. Most bladder cancers are transitional cell carcinomas. They begin in cells that normally make up the inner lining of the bladder. Other types of bladder cancer include squamous cell carcinoma (cancer that begins in thin, flat cells) and adenocarcinoma (cancer that begins in cells that make and release mucus and other fluids). Bladder cancer is a complex disorder with both genetic and environmental influences.
Note=Defects in HRAS are the cause of oral squamous cell carcinoma (OSCC). -
Sequence similarities
Belongs to the small GTPase superfamily. Ras family. -
Post-translational
modificationsPalmitoylated by the ZDHHC9-GOLGA7 complex. A continuous cycle of de- and re-palmitoylation regulates rapid exchange between plasma membrane and Golgi.
S-nitrosylated; critical for redox regulation. Important for stimulating guanine nucleotide exchange. No structural perturbation on nitrosylation. -
Cellular localization
Cell membrane. Golgi apparatus membrane. The active GTP-bound form is localized most strongly to membranes than the inactive GDP-bound form (By similarity). Shuttles between the plasma membrane and the Golgi apparatus. - Information by UniProt
-
Database links
- Entrez Gene: 396229 Chicken
- Entrez Gene: 100298939 Cow
- Entrez Gene: 506322 Cow
- Entrez Gene: 403735 Dog
- Entrez Gene: 403872 Dog
- Entrez Gene: 100135584 Guinea pig
- Entrez Gene: 3265 Human
- Entrez Gene: 3845 Human
see all -
Alternative names
- C BAS/HAS antibody
- C HA RAS1 antibody
- C-BAS/HAS antibody
see all
Images
-
All lanes : Anti-Ras (mutated G12D) antibody (ab221163) at 1/5000 dilution
Lane 1 : Non-transfected 293T whole cell extract
Lane 2 : Ras wild type transfected 293T whole cell extract
Lane 3 : Ras mutated G12D transfected 293T whole cell extract
Lysates/proteins at 30 µg per lane.
Secondary
All lanes : HRP-conjugated anti-rabbit IgG antibody
Predicted band size: 21 kDa12% SDS-PAGE.
-
Anti-Ras (mutated G12D) antibody (ab221163) at 1/500 dilution + AsPC-1 whole cell extract at 30 µg
Secondary
HRP-conjugated anti-rabbit IgG antibody
Predicted band size: 21 kDa12% SDS-PAGE.
-
Immunohistochemical analysis of paraffin-embedded human colon cancer tissue labeling Ras (mutated G12D) with ab221163 at 1/1000 dilution.
-
Immunohistochemical analysis of paraffin-embedded human colon cancer tissue labeling Ras (mutated G12D) with ab221163 at 1/1000 dilution.
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (9)
ab221163 has been referenced in 9 publications.
- Shibata O et al. Establishment of a pancreatic cancer animal model using the pancreas-targeted hydrodynamic gene delivery method. Mol Ther Nucleic Acids 28:342-352 (2022). PubMed: 35474735
- Wang X et al. Vaginal Squamous Cell Carcinoma Develops in Mice with Conditional Arid1a Loss and Gain of Oncogenic Kras Driven by Progesterone Receptor Cre. Am J Pathol 191:1281-1291 (2021). PubMed: 33882289
- Kim MJ et al. PAF remodels the DREAM complex to bypass cell quiescence and promote lung tumorigenesis. Mol Cell 81:1698-1714.e6 (2021). PubMed: 33626321
- Singh K et al. Point Mutation Specific Antibodies in B-Cell and T-Cell Lymphomas and Leukemias: Targeting IDH2, KRAS, BRAF and Other Biomarkers RHOA, IRF8, MYD88, ID3, NRAS, SF3B1 and EZH2. Diagnostics (Basel) 11:N/A (2021). PubMed: 33801781
- Gaba RC et al. Development and comprehensive characterization of porcine hepatocellular carcinoma for translational liver cancer investigation. Oncotarget 11:2686-2701 (2020). PubMed: 32733642
- Oka M et al. KRAS G12D or G12V Mutation in Human Brain Arteriovenous Malformations. World Neurosurg N/A:N/A (2019). PubMed: 30902772
- Zhao X et al. A CRISPR-Cas13a system for efficient and specific therapeutic targeting of mutant KRAS for pancreatic cancer treatment. Cancer Lett 431:171-181 (2018). WB, IHC . PubMed: 29870774
- Quan S et al. Loss of Sirt2 increases and prolongs a caerulein-induced pancreatitis permissive phenotype and induces spontaneous oncogenic Kras mutations in mice. Sci Rep 8:16501 (2018). PubMed: 30405152
- Tang L et al. IGF-1R promotes the expression of cyclin D1 protein and accelerates the G1/S transition by activating Ras/Raf/MEK/ERK signaling pathway. Int J Clin Exp Pathol 10:11652-11658 (2017). PubMed: 31966523